Apotex Pty Ltd v ICOS Corporation (No 4)

Link copied
Case Copied 12 min read

FEDERAL COURT OF AUSTRALIA

Apotex Pty Ltd v ICOS Corporation (No 4) [2018] FCA 1316

File number: VID 280 of 2016
Judge: BESANKO J
Date of judgment: 24 August 2018
Catchwords:

PATENTS – consideration of final declarations, certifications and orders in proceeding where applicant sought relief by way of declarations of invalidity and orders for revocation of claims in two patents (the ‘946 Patent and the ‘666 Patent)

PRACTICE AND PROCEDURE – where injunctions sought – consideration of matters relating to the terms of the injunctions sought – consideration of whether it is appropriate for final orders to contain a penal notice where the orders include an injunction – where penal notice is in the standard form required by the Federal Court Rules 2011 (Cth) – where penal notice applies to a corporation – where proposed orders contain the usual form of injunctive order in a patent infringement dispute, that is, an order restraining the infringement of the claims in suit – consideration of whether a prohibition relates to the facts of the case which is the subject of the proceeding – consideration of whether a prohibition ought to be made because making or maintaining a commitment or guarantee in connection with an application to list a product on either the Schedule of Pharmaceutical Benefits or the Repatriation Schedule of Pharmaceutical Benefits (Schedules) is not an infringement of a patent

Legislation: Federal Court Rules 2011 (Cth) rr 41.06, 41.08
Cases cited:

Apotex Pty Ltd v ICOS Corporation (No 3) [2018] FCA 1204

Coflexip SA v Stolt Comex Seaway MS Ltd [2001] RPC 9

Janssen Securities Ireland UC v Alphapharm Pty Ltd [2017] FCA 1399

Warner-Lambert Company LLC v Apotex Pty Ltd [2017] FCAFC 58; (2017) 249 FCR 17

Date of hearing: 22 August 2018
Registry: Victoria
Division: General Division
National Practice Area: Intellectual Property
Sub-area: Patents and associated Statutes
Category: Catchwords
Number of paragraphs: 7
Counsel for the Applicant:/Cross-Respondent Mr N Murray
Solicitor for the Applicant/Cross-Respondent: Herbert Smith Freehills
Counsel for the Respondent/Cross-Claimant: Mr J Cooke
Solicitor for the Respondent/Cross-Claimant: Wrays Lawyers

ORDERS

VID 280 of 2016
BETWEEN:

APOTEX PTY LTD (ACN 096 916 148)

Applicant

AND:

ICOS CORPORATION

Respondent

AND BETWEEN:

ICOS CORPORATION

Cross-Claimant

AND: APOTEX PTY LTD (ACN 096 916 148)
Cross-Respondent

JUDGE:

BESANKO J

DATE OF ORDER:

24 AUGUST 2018

THE COURT DECLARES THAT:

1.The applicant/cross-respondent has threatened to infringe each of claims 1-6, 8-17, 19-29 and 31-35 of Australian Patent No. 769946 (‘946 Patent).

2.The applicant/cross-respondent has threatened to infringe each of claims 1-3, 5-8, 10-12, 14-18 and 24-38 of Australian Patent No. 773666 (‘666 Patent).

THE COURT CERTIFIES THAT:

3.Pursuant to section 19(1) of the Patents Act 1990 (Cth), the validity of each of claims 1-6, 8-17, 19-29 and 31-35 of the ‘946 Patent was questioned unsuccessfully in this proceeding.

4.Pursuant to section 19(1) of the Patents Act 1990 (Cth), the validity of each of claims 1-3, 5-8, 10-12, 14-18 and 24-38 of the ‘666 Patent was questioned unsuccessfully in…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Apotex Pty Ltd v ICOS Corporation (No 4) and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2018] FCA 1316
Decision Date

CaseChat Overview and Summary

Apotex Pty Ltd sought relief by way of declarations of invalidity and orders for revocation of claims in two patents, the ‘946 Patent and the ‘666 Patent, held by ICOS Corporation. The Federal Court was tasked with determining the legal issues surrounding the validity of these patents and the appropriate relief to be granted. The central issues included whether the patents were valid, whether they had been infringed, and the appropriate form of injunctive relief and penal notices. The Court found that the patents were valid, had been infringed, and granted specific injunctive relief as requested by the patentee, ICOS Corporation. The Court considered the standard form of injunctive orders and penal notices, ultimately deciding that the inclusion of a penal notice was appropriate in this case, given the nature of the infringement and the need for effective deterrence.

The Court addressed the form of the injunctive orders, ensuring they were tailored to the specific facts of the case. It noted that the usual form of injunctive order in patent infringement disputes, which restrains the infringement of the claims in suit, was appropriate. The Court also considered the appropriateness of the penal notice, given that it applied to a corporation and was in the standard form required by the Federal Court Rules 2011. The Court concluded that a prohibition against making or maintaining a commitment or guarantee in connection with an application to list a product on the Schedule of Pharmaceutical Benefits or the Repatriation Schedule of Pharmaceutical Benefits was not an infringement of the patents. The final orders included detailed injunctions against the infringing activities and specific costs orders, with additional conditions on the disclosure and publication of certain documents to protect sensitive information.

Orders

Orders of the court

5. The applicant/cross-respondent, whether by itself, its directors, officers, servants, agents or otherwise, be restrained from infringing or threatening to infringe any of claims 1-6, 8-17, 19-29 and 31-35 of the ‘946 Patent, including, in particular, from engaging in any of the following acts within Australia without the licence or authority of the patentee during the term of the ‘946 Patent:

(a) selling, supplying or otherwise disposing of any Tadalafil ‘946 Product (as defined in Annexure A);

(b) offering to sell, supply or otherwise dispose of any Tadalafil ‘946 Product;

(c) using, importing or otherwise exploiting any Tadalafil ‘946 Product;

(d) keeping any Tadalafil ‘946 Product for the purpose of doing any of the acts referred to in sub-paragraphs (a) to (c) above;

(e) authorising any other person to do any act referred to in sub-paragraphs (a)-(d) above; and

(f) procuring or inducing or joining in a common design with any other person to do any act referred to in sub-paragraphs (a)-(d) above.

6. The applicant/cross-respondent, whether by itself, its directors, officers, servants, agents or otherwise, be restrained from infringing or threatening to infringe claims 1-3, 5-8, 10-12, 14-18 and 24-38 of the ‘666 Patent, including, in particular, from engaging in any of the following acts within Australia without the licence or authority of the patentee during the term of the ‘666 Patent:

(a) selling, supplying or otherwise disposing of any Tadalafil ‘666 Product (as defined in Annexure A);

(b) offering to sell, supply or otherwise dispose of any Tadalafil ‘666 Product;

(c) using, importing or otherwise exploiting any Tadalafil ‘666 Product;

(d) keeping any Tadalafil ‘666 Product for the purpose of doing any of the acts referred to in sub-paragraphs (a) to (c) above;

(e) authorising any other person to do any act referred to in sub-paragraphs (a)-(d) above; and

(f) procuring or inducing or joining in a common design with any other person to do any act referred to in sub-paragraphs (a)-(d) above.

7. The respondent/cross-claimant’s Notice of Cross-claim dated 11 July 2016, as amended on 16 December 2016 and 17 May 2017, be otherwise dismissed.

8. The applicant’s Originating Application dated 1 April 2016 be dismissed.

9. Subject to:

(a) Order 5 of the orders made by the court in this proceeding on 15 December 2016;

(b) Order 3 of the orders made by the court in this proceeding on 9 May 2017; and

(c) Order 13 of the orders made by the court in this proceeding on 17 May 2017;

the applicant/cross-respondent pay the respondent/cross-claimant’s costs of the proceeding, including any reserved costs, as agreed or taxed on a party-party basis.

10. The bank guarantee referred to in paragraph 4 of the orders made by the Court in this proceeding on 23 October 2017 be discharged.

11. Pursuant to section 37AF of the Federal Court of Australia Act 1976 (Cth), Annexure E of Besanko J’s judgment dated 14 August 2018:

(a) will be disclosed to the following persons only:

(i) any judge, employee or other personnel of this Court;

(ii) the respondent, including its employees and external legal representatives;

(iii) Eli Lilly and Company and its related entities, including their employees and external legal representatives;

(iv) external legal representatives of the applicant for the purposes of the proceeding and any appeal therefrom; and

(v) such other persons authorised by the respondent or Eli Lilly and Company, or as the Court may order; and

(b) will not be published, made open to public inspection or disclosed in open Court or disclosed in the open part of any Court transcript.

12. Order 11 is made on the ground of being necessary to prevent prejudice to the proper administration of justice within the meaning of section 37AG(1)(a) of the Federal Court of Australia Act 1976 (Cth).

13. Order 11 will continue until further order.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Annexure A

Tadalafil ‘946 Products

Apotex 20 mg ED Products

ARTG Registration No. 205873

ARTG Registration No. 205886

ARTG Registration No. 205876

ARTG Registration No. 205888

ARTG Registration No. 205877

Apotex 10 mg ED Products

ARTG Registration No. 205852

ARTG Registration No. 205864

ARTG Registration No. 205853

ARTG Registration No. 205880

ARTG Registration No. 205858

Apotex 5 mg ED Products

ARTG Registration No. 205850

ARTG Registration No. 205878

ARTG Registration No. 205854

ARTG Registration No. 205885

ARTG Registration No. 205857

Apotex 2.5 mg ED Products

ARTG Registration No. 205861

ARTG Registration No. 205874

ARTG Registration No. 205869

ARTG Registration No. 205887

ARTG Registration No. 205870

Apotex PAH Products

ARTG Registration No. 205856

ARTG Registration No. 205868

ARTG Registration No. 205859

ARTG Registration No. 205872

ARTG Registration No. 205865

ARTG Registration No. 205875

Tadalafil ‘666 Products

Apotex 20 mg ED Products

ARTG Registration No. 205873

ARTG Registration No. 205886

ARTG Registration No. 205876

ARTG Registration No. 205888

ARTG Registration No. 205877

Apotex 10 mg ED Products

ARTG Registration No. 205852

ARTG Registration No. 205864

ARTG Registration No. 205853

ARTG Registration No. 205880

ARTG Registration No. 205858

Apotex 5 mg ED Products

ARTG Registration No. 205850

ARTG Registration No. 205878

ARTG Registration No. 205854

ARTG Registration No. 205885

ARTG Registration No. 205857

Apotex 2.5 mg ED Products

ARTG Registration No. 205861

ARTG Registration No. 205874

ARTG Registration No. 205869

ARTG Registration No. 205887

ARTG Registration No. 205870

Apotex PAH Products

ARTG Registration No. 205856

ARTG Registration No. 205868

ARTG Registration No. 205859

ARTG Registration No. 205872

ARTG Registration No. 205865

ARTG Registration No. 205875

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.